Latest News Archive

Please select Category, Year, and then Month to display items

UFS amends the retirement age for all staff members to 65

10 December 2021 | Story Lacea Loader

The Council of the University of the Free State (UFS) approved the retirement age of all staff members to 65 this week.

“The current retirement age for staff members of the UFS is 65 years for those appointed prior to 1 June 1998, and 60 years for those appointed after 1 June 1998. The Council’s decision to amend the retirement age to 65 comes after an extensive benchmarking process involving the university’s two labour unions, NEHAWU and UVPERSU, which requested that the retirement age of all staff members be adjusted to 65,” said Prof Francis Petesen, UFS Rector and Vice-Chancellor.

This amendment brings the university in line with other universities and will assist in overcoming a negative impact on the recruitment and attraction of high-calibre academic and specialist staff.

Parallel to the amendment of the retirement age in the Conditions of Services, the university is also adapting the allocation of vacation leave. “We are currently facing a challenge in terms of the provision of the staff leave liability, which has a major financial implication for the UFS. In consultation with stakeholder unions the accumulation of vacation leave has been adjusted to a maximum of five days per year,” said Prof Petersen.

The new retirement age to 65 and the adjusted accumulated vacation leave days will be affected from 1 January 2022. Staff who are set to retire on 31 December 2021 may opt to continue to the age 65. This amendment will not apply to staff that may have already retired.

Adjusted vacation as from 1 January 2022:

Academic staff:

Current number of vacation days: 42

Approved Leave Days

Number of vacation days: 30

Additional research leave days: 12 (non-cumulative and expires at the end of each calendar year)

Support staff:

Deputy Director and higher levels

Peromnes Level: 1 – 6

Current number of leave vacation days: 36

Approved number of vacation days: 30

Assistant Director to Officer

Peromnes Level: 7 – 14

Current number of leave vacation days: 30 - 28

Approved number of vacation days: 28

Service Workers

Peromnes Level: 15 - 18

Current number of leave vacation days: 24

Approved number of vacation days: 24

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children

2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept